Axsome Therapeutics, Inc.
AXSM
#1838
Rank
$10.851 B
Marketcap
United States
Country
$207.15
Share price
-3.99%
Change (1 day)
74.99%
Change (1 year)
Categories
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive…
Key Metrics
Trailing P/E
—
Forward P/E
41.65
EPS (TTM)
$-3.75
Forward EPS
$5.03
Price / Book
131.61
EV / EBITDA
-61.3x
Beta
0.71
Dividend Yield
—
Return on Equity
-245.10%
Return on Assets
-16.31%
Debt / Equity
269.73
Current Ratio
1.43
Gross Margin
93.24%
Operating Margin
-23.42%
Net Profit Margin
-24.68%
Free Cash Flow
$-4,581,750
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 17 – Sep 16
-3.06%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$638.496M
Latest Net Income$-183,174,000
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Axsome Therapeutics, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
AXSM
No recent news available. Set FINNHUB_API_KEY to enable news.
